Mechanistically, CTLA-4, PD-1, and PD-L1 inhibitors enhance T-cell proliferation and activation against malignant antigens; the T-cells are reinvigorated to recognize cancer cells, impeding tumor evasion from the immune system. Here, CD274 is linked to neoplasm.